Hormone Replacement Therapy in Military Personnel: Evidence for Benefits
Based on available evidence, HRT demonstrates clear benefits for both men and women, though the evidence provided does not specifically address military populations—the benefits shown in general populations would reasonably apply to service members with hypogonadism (men) or menopausal symptoms (women).
For Men: Testosterone Replacement Therapy
Testosterone replacement therapy in hypogonadal men produces documented improvements in libido, bone density, muscle mass, body composition, mood, erythropoiesis, and cognition 1. These benefits are particularly relevant for military personnel who require maintained physical performance and cognitive function.
Key Benefits in Hypogonadal Men:
- Improved muscle mass and bone density - critical for physical readiness
- Enhanced libido and erectile function - quality of life improvement
- Better mood and reduced depression - mental health benefit
- Increased sense of vitality and energy - operational readiness
- Improved cognition - decision-making capability
The prevalence of hypogonadism increases with age, affecting an estimated 2-4 million men in the United States, yet only 5% receive treatment 1. For military personnel experiencing symptoms of low testosterone (diminished energy, reduced muscle mass, depression, erectile dysfunction), treatment addresses both quality of life and functional capacity.
Important Caveat:
No large-scale, long-term studies have assessed risks in men receiving testosterone therapy, particularly regarding prostate cancer stimulation 1. Monitoring is essential, though specific military population data is absent from the provided evidence.
For Women: Hormone Replacement Therapy
The evidence for women is more complex and age-dependent. When initiated within 10 years of menopause, HRT reduces all-cause mortality and risks of coronary disease, osteoporosis, and dementias 2.
Documented Benefits:
- Fracture risk reduction: 27% reduction in nonvertebral fractures, with specific reductions in hip (RH 0.66), vertebral (RH 0.66), and total fractures (RH 0.76) 3
- Colorectal cancer reduction: 34% risk reduction 4
- Alzheimer's disease reduction: 20-60% risk reduction 4
- Relief of menopausal symptoms: vasomotor instability, sexual dysfunction, mood issues, fatigue 5
- Bone density maintenance: even when started after age 60 4
Critical Timing Factor:
Age at HRT initiation is critical in determining benefit-risk ratio 2. The Women's Health Initiative (WHI) tested HRT started a decade or more after menopause—not the typical clinical scenario. For recently menopausal women (within 10 years), the benefit profile is substantially more favorable.
Risks to Consider:
For women ages 50-79, per 10,000 women taking estrogen-progestin for 1 year 3:
- 7 additional CHD events
- 8 more strokes
- 8 more pulmonary emboli
- 8 more invasive breast cancers
- BUT 6 fewer colorectal cancers and 5 fewer hip fractures
The slight increase in breast cancer risk (with 5+ years use) disappears following cessation of therapy 4.
Military-Specific Considerations
While the provided evidence lacks military-specific studies, the documented benefits directly address operational readiness concerns:
For male service members: Maintained muscle mass, bone density, energy, and cognitive function support physical and mental performance requirements.
For female service members: Fracture prevention, maintained bone density, and symptom relief support continued operational capability during the menopausal transition.
Clinical Approach
Use the lowest effective dose for the shortest time needed when treating menopausal symptoms 3. For men with documented hypogonadism (low serum testosterone with associated symptoms), testosterone replacement addresses multiple functional domains simultaneously 1.
The decision requires individualized risk-benefit assessment, but the evidence supports HRT use in appropriately selected military personnel—hypogonadal men and recently menopausal women—to maintain quality of life and functional capacity 2, 4, 6.